|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Emissions control has long been an important management issue for pharmaceutical manufacturers in Europe and beyond, but emerging legislation implemented throughout EU member states is forcing the industry to take a closer look at abatement technologies in search of solutions which will ensure compliance not just now, but in the future too.
Legislation puts Focus on Solvent Recovery
The manufacture of pharmaceutical products is reliant on a number of organic solvents, producing emissions in a number of process areas - from reactor vents to storage tanks and vacuum pumps. Dichloromethane, methanol, ethyl acetate, acetone, toluene, xylene, triethylamine, tetrahydrofurane, butyl acetate and isopropanol are among the VOCs regularly used by pharmaceutical manufacturers and legislation is limiting these emissions year on year. Industrial emissions to the atmosphere first became a focus of environmental regulation with the introduction of the Clean Air Act in 1993. Since then increasing concern about the effect of air pollutants on the environment has led to the development of the UK's National Air Quality Strategy, setting targets which are to be achieved by 2005.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’
CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief
Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded
generic manufacturer, says favourable conditions in the UAE are
resulting in a boom of pharmaceutical manufacturing throughout the
region. Government incentive schemes to increase domestic production,
coupled with a brand friendly environment and rising healthcare needs is
fuelling surging demand – with many new companies and plants launching
in the last two years alone.
More info >> |
|
 |
White Papers |
 |
|
Migration safe pharmaceutical labels improve patient safety
UPM Raflatac
Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >> |
|
 |
Industry Events |
 |
DIA 2019 Global Annual Meeting
23-27 June 2019, San Diego Convention Center
DIA 2019 is more than just a meeting: it’s where
brilliant minds come together to create solutions. Thousands of global
innovators will convene to engage in discussions on today’s hottest topics in
the life sciences field, propose ways to combat daily challenges, and network
to create lasting connections.
More info >> |
|
|
